Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions for maintenance of electrolyte balance and cellular function; dextrose provides calories and serves as a source of glucose; sodium chloride provides sodium and chloride ions for maintenance of osmotic pressure and acid-base balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Source of electrolytes and calories in parenteral nutrition,Treatment and prevention of hypokalemia,Maintenance of fluid and electrolyte balance
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion. Dose depends on electrolyte deficits and fluid requirements. Typical adult maintenance: 1-2 m Eq/kg/day potassium chloride, dextrose 10% at 100-200 m L/hour, sodium chloride 0.2% as needed. Rate not to exceed 10 m Eq/hour potassium chloride.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Potassium has no defined terminal elimination half-life because it is an endogenous ion under homeostatic control; redistribution half-life is approximately 1-2 hours. Dextrose: plasma half-life is <15 minutes due to rapid cellular uptake and metabolism. Sodium: no defined half-life due to tight renal regulation.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the Krebs cycle; potassium and sodium are excreted primarily by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Potassium is primarily excreted renally (90%) via glomerular filtration and tubular secretion; approximately 10% is eliminated in feces via gastrointestinal secretion. Dextrose is completely metabolized to carbon dioxide and water, with negligible renal excretion. Sodium is excreted renally, with excretion matching intake under normal regulation.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Potassium: negligible protein binding (<2%). Dextrose: not bound. Sodium: not bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Potassium: Vd ~0.5 L/kg in total body water; distributes predominantly intracellularly (98% of total body potassium is intracellular). Dextrose: Vd ~0.2 L/kg (extracellular fluid). Sodium: Vd ~0.2 L/kg (extracellular fluid).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% for all components. Not administered orally as this formulation; oral potassium has bioavailability ~90% but not applicable here.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR > 50 m L/min: no adjustment. GFR 10-50 m L/min: reduce potassium dose by 25-50% and monitor serum potassium closely. GFR < 10 m L/min: avoid use or use with extreme caution; potassium dose should not exceed 20 m Eq/day unless monitored intensively.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: caution; monitor potassium and ammonia levels. Child-Pugh Class C: use with extreme caution; dextrose may exacerbate hepatic encephalopathy; reduce infusion rate.
No dosage adjustment required for hepatic impairment.
Weight-based intravenous infusion. Potassium: 0.5-1 m Eq/kg/day for maintenance; not to exceed 1-2 m Eq/kg/day. Dextrose 10%: 100-200 m L/kg/day for infants, 60-100 m L/kg/day for older children. Sodium chloride 0.2%: adjust based on sodium needs. Infusion rate: do not exceed 0.5 m Eq/kg/hour for potassium.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Start at lower end of dosing range due to age-related decline in renal function. Monitor serum potassium, renal function, and fluid status closely. Avoid rapid infusion; typical rate not exceeding 5 m Eq/hour potassium chloride. Reduce dextrose load if glucose intolerance present.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Do not administer unless solution is clear and container undamaged,Use with caution in patients with renal insufficiency, heart failure, or conditions predisposing to hyperkalemia,Monitor serum potassium, glucose, and electrolytes during therapy,Risk of hyperkalemia if administered too rapidly or in excessive amounts
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperkalemia,Hypersensitivity to any component,Severe renal impairment with oliguria or anuria,Addison's disease,Concurrent use of potassium-sparing diuretics (relative contraindication)
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No significant food interactions. However, potassium-rich foods (e.g., bananas, oranges, leafy greens) may contribute to hyperkalemia; dietary potassium intake should be monitored.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Potassium chloride, dextrose, and sodium chloride at these concentrations are physiologic components of body fluids. No teratogenic risk has been associated with these components at standard infusion rates. However, maternal electrolyte disturbances (e.g., hyperkalemia, hyperglycemia) can adversely affect the fetus. First trimester: No specific fetal risk; use only if clearly needed. Second/third trimester: Monitor maternal electrolytes and glucose to avoid fetal distress.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Potassium, dextrose, and sodium are normal constituents of breast milk. No specific M/P ratio is available. Use during lactation is considered safe when administered as per standard clinical practice. However, high maternal serum levels could alter milk composition; avoid excessive infusion rates.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy does not typically require dose adjustment for this maintenance solution. However, increased plasma volume and GFR may necessitate titration of potassium and dextrose based on maternal electrolyte and glucose monitoring. Avoid fluid overload in preeclampsia or cardiac conditions.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This solution is a balanced maintenance fluid providing potassium, dextrose, and sodium. Monitor serum potassium closely, especially in renal impairment. Avoid rapid infusion in patients with cardiac conditions. Use with caution in patients with hyperkalemia or renal failure. The dextrose component may cause hyperglycemia in diabetic patients.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Report any chest pain, irregular heartbeat, or muscle weakness immediately.,Inform your doctor if you have kidney problems or diabetes.,This fluid contains sugar; blood sugar may increase.,Do not stop or adjust the infusion rate without medical advice.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions for maintenance of electrolyte balance and cellular function; dextrose provides calories and serves as a source of glucose; sodium chloride provides sodium and chloride ions for maintenance of osmotic pressure and acid-base balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion. Dose depends on electrolyte deficits and fluid requirements. Typical adult maintenance: 1-2 m Eq/kg/day potassium chloride, dextrose 10% at 100-200 m L/hour, sodium chloride 0.2% as needed. Rate not to exceed 10 m Eq/hour potassium chloride.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride at these concentrations are physiologic components of body fluids. No teratogenic risk has been associated with these components a. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.